Whalen Wealth Management Inc. Takes Position in Johnson & Johnson $JNJ

Whalen Wealth Management Inc. acquired a new stake in shares of Johnson & Johnson (NYSE:JNJ) during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund acquired 4,320 shares of the company’s stock, valued at approximately $894,000.

Other institutional investors have also modified their holdings of the company. Abich Financial Wealth Management LLC bought a new position in shares of Johnson & Johnson during the 3rd quarter valued at about $26,000. Evolution Wealth Management Inc. bought a new stake in Johnson & Johnson in the 2nd quarter valued at approximately $27,000. Clayton Financial Group LLC bought a new stake in Johnson & Johnson in the 3rd quarter valued at approximately $28,000. Semmax Financial Advisors Inc. lifted its stake in Johnson & Johnson by 55.0% in the 2nd quarter. Semmax Financial Advisors Inc. now owns 203 shares of the company’s stock valued at $31,000 after acquiring an additional 72 shares in the last quarter. Finally, Turning Point Benefit Group Inc. bought a new stake in Johnson & Johnson in the 3rd quarter valued at approximately $41,000. Institutional investors own 69.55% of the company’s stock.

Johnson & Johnson Trading Down 1.0%

Shares of Johnson & Johnson stock opened at $238.47 on Wednesday. The company has a quick ratio of 0.77, a current ratio of 1.03 and a debt-to-equity ratio of 0.48. The stock has a market cap of $574.38 billion, a P/E ratio of 21.58, a P/E/G ratio of 2.41 and a beta of 0.34. Johnson & Johnson has a 12-month low of $141.50 and a 12-month high of $251.71. The business’s 50 day moving average is $240.53 and its 200-day moving average is $214.17.

Johnson & Johnson (NYSE:JNJ) last posted its earnings results on Saturday, January 31st. The company reported $2.46 earnings per share for the quarter. The business had revenue of $24.28 billion for the quarter. Johnson & Johnson had a return on equity of 33.04% and a net margin of 28.46%. Equities research analysts predict that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

More Johnson & Johnson News

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: Major analyst upgrades and price?target raises are boosting sentiment — Citigroup raised its JNJ target to $285 (maintained Buy), signaling meaningful upside from current levels. Citigroup Adjusts Price Target on Johnson & Johnson to $285 From $274, Maintains Buy Rating
• Positive Sentiment: Additional analyst support: Guggenheim nudged its target to $244 and TD Cowen reiterated a Buy with a $250 target, adding to buying pressure from institutional research. Guggenheim Adjusts Price Target on Johnson & Johnson to $244 From $240, Maintains Buy Rating
• Positive Sentiment: Regulatory and commercial wins: J&J launched the next?gen Varipulse/VARIPULSE Pro in Europe after CE Mark clearance, supporting MedTech sales growth. Johnson & Johnson brings next-gen Varipulse PFA catheter to Europe
• Positive Sentiment: Clinical/regulatory pipeline progress: J&J secured a permanent U.S. reimbursement code for INLEXZO (bladder cancer), reported 52?week efficacy for ICOTYDE in psoriasis, and struck a distribution deal for SIRTURO in Japan — tangible evidence of specialty?therapies momentum. Johnson & Johnson Updates Key Specialty Therapies And Undervaluation Signals For Investors
• Positive Sentiment: Visibility and flow: coverage in S&P 500 trend pieces and low?volatility blue?chip lists is drawing attention from dividend and defensive equity buyers. Johnson & Johnson (NYSE:JNJ) Gains Visibility As S&P 500 Today Trends Shift
• Neutral Sentiment: Technicals/buy?zone mentions: market commentary (Investors.com) flags JNJ as in/near buy zones — useful for traders but not inherently fundamental. Dow Jones Medical Giant Johnson & Johnson Eyes Latest Buy Point
• Neutral Sentiment: Analyst consensus stays constructive (consensus “Moderate Buy”), which supports a steady bid but limits surprise upside unless fundamentals accelerate. Johnson & Johnson (NYSE:JNJ) Receives Consensus Rating of “Moderate Buy” from Analysts

Insider Buying and Selling

In other Johnson & Johnson news, EVP Timothy Schmid sold 22,623 shares of the company’s stock in a transaction on Wednesday, February 18th. The stock was sold at an average price of $244.33, for a total value of $5,527,477.59. Following the transaction, the executive vice president directly owned 26,769 shares of the company’s stock, valued at $6,540,469.77. This represents a 45.80% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Also, EVP Vanessa Broadhurst sold 6,197 shares of the company’s stock in a transaction on Tuesday, February 17th. The shares were sold at an average price of $243.39, for a total value of $1,508,287.83. Following the completion of the transaction, the executive vice president directly owned 23,003 shares in the company, valued at approximately $5,598,700.17. This represents a 21.22% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 30,142 shares of company stock worth $7,360,528 over the last three months. 0.16% of the stock is owned by insiders.

Analyst Ratings Changes

JNJ has been the topic of several analyst reports. Freedom Capital cut shares of Johnson & Johnson from a “strong-buy” rating to a “hold” rating in a research report on Friday, January 16th. Guggenheim upped their price objective on Johnson & Johnson from $240.00 to $244.00 and gave the stock a “buy” rating in a research note on Tuesday. HSBC upped their price objective on Johnson & Johnson from $265.00 to $280.00 and gave the stock a “buy” rating in a research note on Tuesday, March 17th. Argus upped their price objective on Johnson & Johnson from $210.00 to $240.00 in a research note on Friday, January 23rd. Finally, Wall Street Zen cut Johnson & Johnson from a “buy” rating to a “hold” rating in a research note on Saturday, February 14th. One equities research analyst has rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and nine have given a Hold rating to the stock. According to data from MarketBeat.com, Johnson & Johnson currently has a consensus rating of “Moderate Buy” and an average price target of $237.57.

Johnson & Johnson Profile

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.